The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …

In the United States, breast cancer is among the most frequently diagnosed cancers in
women. Breast cancer is classified into four major subtypes: human epidermal growth factor …

Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …

Members of the human epidermal growth factor receptor (HER) family, which includes HER1
(also known as EGFR), HER2, HER3 and HER4, have played a central role in regulating cell …

Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of
cancer death among women worldwide. Globally, BC is the second most frequent cancer …

Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in
approximately 15–20% of breast cancer cases. HER2 is a member of the epidermal growth …

Simple Summary HER2-positive metastatic breast cancer remains a nearly incurable
disease. In this sense, new treatments have been developed in recent years. On the one …